Study S001828

Efficacy and Safety of HRS9531 in Overweight or Obese Participants: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06396429
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 567
Start: 2024-05-13
Primary completion: 2025-07-07
Lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions: Overweight or Obesity
Interventions: DRUG:HRS9531 injection; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Percentage change from baseline in weight after 48 weeks of treatment [Baseline, Week 48]
Proportion of subjects with weight loss of≥5% from baseline after 48 weeks of treatment [Week 48]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.